Cure Team

William (Bill) Amsbaugh is a Partner and Chief Technology Officer (CTO) at Cure Ventures where he heads the firm’s bioinformatics efforts. His career spans 25 years across a variety of technical domains combining his training as an analytical chemist with his expertise in computer science. Bill has been focused on accelerating drug discovery and commercialization […]

Mr. Fallace (Dave) is a Managing Partner and Co-Founder of Cure Ventures. He has made investments in venture capital and alternative asset funds for over 20 years. He served as a member of the investment committee of several large multibillion-dollar firms overseeing alternative investment portfolios. Across these portfolios he made investments as a limited partner

Dr. Jonas (Jeff) is a Partner at Cure Ventures and brings over two decades of experience in R&D leadership and cutting-edge CNS drug discovery and development across medicines and brands that have successfully helped millions of patients, such as Lexapro, Vyvanse, Zulresso, Zurzuvae and Namenda. Dr. Jonas’ significant company-building and advisory experience has generated considerable

Kayarash is a Senior Associate at Cure Ventures, where he focuses on company creation efforts. His work at Cure is driven by a mission to develop transformative medicines through a culture rooted in scientific rigor, creativity, and patient-centric innovation. Kayarash earned his PhD at the Johns Hopkins University School of Medicine as a National Science

Mr. King (Drew) is a Partner and the Chief Financial Officer of Cure Ventures. He oversees the financial and operational functions at the Firm and our early-stage portfolio companies. Drew has over 15 years of experience in finance and operations supporting both private and capital market funds. He most recently was the Vice President of

Dr. King (Virginia Lyle) is a Senior Associate of Cure Ventures with over 10 years of research experience. As a member of the Cure Ventures team, Lyle is involved in sourcing new deals, conducting due diligence, and assisting with company creation endeavors. Most recently, she worked at the University of Connecticut as a graduate researcher

Rich’s career in the life science sector spans three decades demonstrating strategic and corporate development leadership within the biotech industry as well as investment leadership at top-performing venture capital firms. He is considered a trusted partner to visionary scientists and entrepreneurs, by being directly involved in the early capital raises of leading prominent biotech start-ups.

Dr. Weihan Liu is an Associate at Cure Ventures, with over ten years of experience in biomedical research. Most recently, Weihan was a consultant at ClearView Healthcare Partners, where he worked with pharma and biotech companies to address critical challenges in drug development and commercialization. Prior to that, he earned his Ph.D. at the University

Dr. Robichaud (Al) is a Partner of Cure Ventures with over three decades of industry experience focused primarily on neuroscience. Prior to joining Cure, he was the founding scientist and Chief Scientific Officer at Sage Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare CNS disorders. While there, Al helped launch the

Dr. Robinson (Sophie) is an Associate at Cure Ventures with over a decade of experience in academic research and industry, both in the United States and abroad. Prior to joining Cure Ventures, Sophie was a doctoral candidate at the German Center of Neurodegenerative Diseases and the Institute for Stroke and Dementia Research in Munich, Germany.